Akari Therapeutics, Plc (AKTX) EPS Estimated At $-1.00

March 20, 2018 - By Peter Erickson

 Akari Therapeutics, Plc (AKTX) EPS Estimated At $ 1.00

Analysts expect Akari Therapeutics, Plc (NASDAQ:AKTX) to report $-1.00 EPS on March, 30.They anticipate $0.92 EPS change or 1,150.00 % from last quarter’s $-0.08 EPS. After having $-0.09 EPS previously, Akari Therapeutics, Plc’s analysts see 1,011.11 % EPS growth. The stock decreased 1.38% or $0.03 during the last trading session, reaching $2.15. About 34,653 shares traded. Akari Therapeutics, Plc (NASDAQ:AKTX) has declined 48.07% since March 20, 2017 and is downtrending. It has underperformed by 64.77% the S&P500.

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat rare and orphan autoimmune and inflammatory diseases. The company has market cap of $32.80 million. The Company’s lead drug candidate is Coversin, a second-generation complement inhibitor that is in Phase II clinical trial for the treatment of autoimmune and inflammatory diseases, including paroxysmal nocturnal hemoglobinuria, guillain barré syndrome, and atypical hemolytic uremic syndrome. It currently has negative earnings. The firm is based in New York, New York.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.